French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior ...
Aelis Farma's Phase 2B trial with AEF0117 for cannabis use disorder (CUD) did not meet primary goals, including reducing cannabis use to one day or less per week. AEF0117 was well-tolerated, but Indivior, which has an option to license the drug, does not expect to exercise it due to lack of separation from placebo.
Reference News
French Biotech Candidate For Cannabis Use Disorder Fails Phase 2B Clinical Trial, Indivior ...
Aelis Farma's Phase 2B trial with AEF0117 for cannabis use disorder (CUD) did not meet primary goals, including reducing cannabis use to one day or less per week. AEF0117 was well-tolerated, but Indivior, which has an option to license the drug, does not expect to exercise it due to lack of separation from placebo.